These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 31433997)
1. Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Loebinger MR; Polverino E; Blasi F; Elborn SJ; Chalmers JD; Tiddens HA; Goossens H; Tunney M; Zhou W; Angyalosi G; Hill AT; Haworth CS; Pulm Pharmacol Ther; 2019 Oct; 58():101834. PubMed ID: 31433997 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of TOBI Podhaler in Loebinger MR; Polverino E; Chalmers JD; Tiddens HAWM; Goossens H; Tunney M; Ringshausen FC; Hill AT; Pathan R; Angyalosi G; Blasi F; Elborn SJ; Haworth CS; Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32855225 [TBL] [Abstract][Full Text] [Related]
3. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Bilton D; Henig N; Morrissey B; Gotfried M Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030 [TBL] [Abstract][Full Text] [Related]
4. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
5. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831 [TBL] [Abstract][Full Text] [Related]
6. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882 [TBL] [Abstract][Full Text] [Related]
8. A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection. Guan WJ; Xu JF; Luo H; Xu XX; Song YL; Ma WL; Liang ZA; Liu XD; Zhang GJ; Zhang XJ; Li RK; Zhu SY; Zhang YJ; Cai XJ; Wei LP; Tian DB; Zhao H; Chen PY; Qu JM; Zhong NS; Chest; 2023 Jan; 163(1):64-76. PubMed ID: 35863486 [TBL] [Abstract][Full Text] [Related]
9. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109 [TBL] [Abstract][Full Text] [Related]
10. Inhaled tobramycin for chronic infection with pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Sangiovanni S; Morales EI; Fernández-Trujillo L Respir Med; 2021 Jan; 176():106283. PubMed ID: 33307314 [TBL] [Abstract][Full Text] [Related]
11. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914 [TBL] [Abstract][Full Text] [Related]
12. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
13. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. McKeage K Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436 [TBL] [Abstract][Full Text] [Related]
14. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE; Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545 [TBL] [Abstract][Full Text] [Related]
15. Bronchiectasis and inhaled tobramycin: A literature review. Elborn JS; Blasi F; Haworth CS; Ballmann M; Tiddens HAWM; Murris-Espin M; Chalmers JD; Cantin AM Respir Med; 2022 Feb; 192():106728. PubMed ID: 34998112 [TBL] [Abstract][Full Text] [Related]
16. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM; Waugh J; Noble S Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360 [TBL] [Abstract][Full Text] [Related]
17. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872 [TBL] [Abstract][Full Text] [Related]